GlassScriptPhysician profile
Neil E Lattin
NPI 1508818162
$999.77
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $32.98 · 2021: $37.90 · 2022: $43.27 · 2023: $93.14 · 2024: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $627.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $230.29 | 2022-2024 | |
| Lilly USA, LLC | $86.48 | 2019-2024 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $80.03 | 2019-2024 | Spravato, Xarelto |
| Novartis Pharmaceuticals Corporation | $66.62 | 2019 | |
| Pfizer INC. | $63.33 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $56.35 | 2019-2024 | Farxiga, Breztri |
| Exact Sciences Corporation | $53.23 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $48.42 | 2021-2023 | Trelegy Ellipta |
| Tactile Systems Technology INC | $37.16 | 2024 | Entre Plus, Flexitouch Plus |
| Merck Sharp & Dohme LLC | $31.44 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Astellas Pharma US INC | $30.22 | 2024 | Veozah |
| Amgen INC. | $27.70 | 2023 | Prolia, Evenity |
| Otsuka America Pharmaceutical, INC. | $24.76 | 2024 | Rexulti |
| Celgene Corporation | $23.57 | 2019 | |
| Ironshore Pharmaceuticals INC. | $19.94 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $18.11 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.81 | 2019 | |
| Allergan, INC. | $15.73 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.38 | 2024 | Xifaxan |
| Novo Nordisk INC | $14.87 | 2020 | |
| Medtronic, INC. | $14.03 | 2022 | |
| Genentech USA, INC. | $13.58 | 2019 | |
| Alkermes, INC. | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Lattin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.